← Tonghua Dongbao Pharmaceutical overview

Tonghua Dongbao Pharmaceutical vs Shanghai Fosun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Tonghua Dongbao Pharmaceutical Co Ltd (600867.CG)

Q3 2026
▲2▼2

FDA approval and strong H1 profit offset by high shareholder pledges

  • US FDA approval opens overseas market Tonghua Dongbao's co-developed insulin aspart injection won US FDA approval, letting it sell in the world's biggest insulin market. Novo Nordisk's US insulin aspart sales were about $1.1 billion last year, so this is a real long-term growth opening, not just a headline.

    This is the biggest new positive force, opening a large new market for the company's insulin products.

  • First-half profit jumps 37% on insulin analogue sales First-half 2026 revenue rose 11.13% to 1.553 billion yuan and net profit rose 37.32% to 296 million yuan. Strong sales of insulin glargine and aspart drove domestic growth, and second-quarter profit rose 55.5%. This shows the core business is performing well.

    The interim results are the clearest evidence of underlying business strength and directly support the stock's value.

  • Controlling shareholder pledges over 93% of its shares Dongbao Group repeatedly released and re-pledged tens of millions of shares, leaving 93.94% of its holdings pledged. That is a warning sign: if the share price falls sharply, the shareholder could face margin calls or forced selling, which would hurt ordinary investors.

    This is the main risk weighing on the stock and a real counterweight to the good news.

  • Project termination and impairment slightly reduce profit Tonghua Dongbao scrapped its THDBH110 capsule development project and wrote off 16.89 million yuan, cutting first-half profit by that amount. It is a small hit next to the 296 million yuan profit, but it shows some pipeline bets are not paying off.

    This is a modest but real negative that partly offsets the strong earnings and shows pipeline risk.

August 2026
▲2▼2

FDA approval and strong H1 profit offset by high shareholder pledges

  • US FDA approval opens overseas market Tonghua Dongbao's co-developed insulin aspart injection won US FDA approval, letting it sell in the world's biggest insulin market. Novo Nordisk's US insulin aspart sales were about $1.1 billion last year, so this is a real long-term growth opening, not just a headline.

    This is the biggest new positive force, opening a large new market for the company's insulin products.

  • First-half profit jumps 37% on insulin analogue sales First-half 2026 revenue rose 11.13% to 1.553 billion yuan and net profit rose 37.32% to 296 million yuan. Strong sales of insulin glargine and aspart drove domestic growth, and second-quarter profit rose 55.5%. This shows the core business is performing well.

    The interim results are the clearest evidence of underlying business strength and directly support the stock's value.

  • Controlling shareholder pledges over 93% of its shares Dongbao Group repeatedly released and re-pledged tens of millions of shares, leaving 93.94% of its holdings pledged. That is a warning sign: if the share price falls sharply, the shareholder could face margin calls or forced selling, which would hurt ordinary investors.

    This is the main risk weighing on the stock and a real counterweight to the good news.

  • Project termination and impairment slightly reduce profit Tonghua Dongbao scrapped its THDBH110 capsule development project and wrote off 16.89 million yuan, cutting first-half profit by that amount. It is a small hit next to the 296 million yuan profit, but it shows some pipeline bets are not paying off.

    This is a modest but real negative that partly offsets the strong earnings and shows pipeline risk.

Latest
▲2▼2

FDA approval and strong H1 profit offset by high shareholder pledges

  • US FDA approval opens overseas market Tonghua Dongbao's co-developed insulin aspart injection won US FDA approval, letting it sell in the world's biggest insulin market. Novo Nordisk's US insulin aspart sales were about $1.1 billion last year, so this is a real long-term growth opening, not just a headline.

    This is the biggest new positive force, opening a large new market for the company's insulin products.

  • First-half profit jumps 37% on insulin analogue sales First-half 2026 revenue rose 11.13% to 1.553 billion yuan and net profit rose 37.32% to 296 million yuan. Strong sales of insulin glargine and aspart drove domestic growth, and second-quarter profit rose 55.5%. This shows the core business is performing well.

    The interim results are the clearest evidence of underlying business strength and directly support the stock's value.

  • Controlling shareholder pledges over 93% of its shares Dongbao Group repeatedly released and re-pledged tens of millions of shares, leaving 93.94% of its holdings pledged. That is a warning sign: if the share price falls sharply, the shareholder could face margin calls or forced selling, which would hurt ordinary investors.

    This is the main risk weighing on the stock and a real counterweight to the good news.

  • Project termination and impairment slightly reduce profit Tonghua Dongbao scrapped its THDBH110 capsule development project and wrote off 16.89 million yuan, cutting first-half profit by that amount. It is a small hit next to the 296 million yuan profit, but it shows some pipeline bets are not paying off.

    This is a modest but real negative that partly offsets the strong earnings and shows pipeline risk.

Shanghai Fosun Pharmaceutical Group Co Ltd (600196.CG)

Q3 2026
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.

August 2026
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.

Latest
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.